Home
Learn More
Features & Pricing
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
August 21, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
Close Move
All Press Releases for March 11, 2008 Subscribe to this News Feed     Subscribe to this Podcast Feed  
 

Replikins Oral Vaccine Synthesized in 7 days protects 91% of Shrimp Against Lethal Virus

Replikins, Ltd. has announced development of a chemically synthesized vaccine specific to a Taura Syndrome virus structure based on its patented Replikins™ technology. When the vaccine was administered orally to shrimp, 91% survived a challenge by the lethal Taura virus. The effectiveness of this vaccine, and its rapid production cycle (7 days), represent an important proof of concept for developing vaccines against a range of rapidly replicating high lethality virus outbreaks.

Boston, MA (PRWEB) March 11, 2008 -- Replikins, Ltd. has announced development of a chemically synthesized vaccine specific to a Taura Syndrome virus structure based on its patented Replikins™ technology. When the vaccine was administered orally to shrimp, 91% survived a challenge by the lethal Taura virus. The specificity of the protective effect was established in control groups by chemically blocking the active regions in the vaccine, and as a result the protective effect was lost in these control groups. The effectiveness of this vaccine, and its rapid production cycle (7 days), represent an important proof of concept for developing vaccines against a range of rapidly replicating high lethality virus outbreaks.

For counteracting emerging infectious disease, early detection and rapid response are critical. Replikin contributions to date are both in early detection and rapid response: 1) Advance warning previously was not possible until it was found in H5N1 influenza that an increase in the virus replikin concentration signalled one year in advance that the outbreak was coming, and indicated the country in which this would occur (FluForecast™, Indonesia). 2) The production of vaccines by other methods has required 3 to 12 months, by which time the epidemic may have come and gone, or the vaccine effectiveness reduced or lost because the target changed due to mutation. In contrast, the replikins vaccine found effective here was manufactured synthetically in 7 days.

Viruses lethal to shrimp have been responsible for large losses to aquaculture worldwide. Replikins is forming a division to focus on these viruses. The company is also pursuing development of synthetic vaccine products based on replikin epitopes, Syntopes™, for the control of fish hemorrhagic viruses and other lethal aquatic microorganisms.

###

Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/VGhpci1Db3VwLUNyYXMtTG92ZS1Ib3JyLVplcm8=

Technorati Tags

Bookmark -  Del.icio.us | Digg | Furl It | Spurl | RawSugar | Simpy | Shadows | Blink It | My Web


OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
BlogThis
ShareIt

Share The News

Submit this press release easily to any of these major bookmarking and social media sites.

CONTACT INFORMATION
Dr. Samuel Bogoch
Replikins Ltd.
646-320-5910
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your login.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these releases. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright